Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Rhea-AI Summary
Ensysce Biosciences (NASDAQ: ENSC) received a new $5.3 million installment from the National Institute on Drug Abuse (NIDA), marking the third consecutive year of support and completing a multi‑year $15.1 million federal grant for its MPAR® overdose‑protection technology and lead candidate PF614‑MPAR.
According to Ensysce, this funding will finance completion of the PF614‑MPAR‑102 clinical study and required long‑term non‑clinical work supporting a future New Drug Application. PF614‑MPAR, which has U.S. FDA Breakthrough Therapy designation, is designed to actively limit opioid release in oral overdose situations via a proprietary chemical control mechanism.
Positive
- $5.3 million third‑year NIDA installment received
- Multi‑year NIDA grant completed at $15.1 million total funding
- Funding supports completion of PF614‑MPAR‑102 clinical study
- Grant covers long‑term non‑clinical work toward PF614‑MPAR NDA
- PF614‑MPAR holds U.S. FDA Breakthrough Therapy designation
Negative
- None.
News Explained
The grant is complete as an award, but the release does not establish that its final installment is already cash on Ensysce’s balance sheet.
The July 14 release reports receipt of a NIDA Notice of Award for the final
Against Ensysce’s first-quarter figures, reported cash and equivalents equaled
Sources and calculations
- July 14 Ensysce Biosciences NIDA funding release (2026-07-14)
- Ensysce Biosciences first-quarter 2026 financial results (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $15,100,000 / ($3,500,925 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $745,482 / ($3,500,925 / 90) = [object Object]
Market reaction after NIDA grant funding award: ENSC +6.17% in the Jul 14 session
In the Jul 14 session, ENSC gained 6.17%, reflecting a notable positive market reaction. Argus tracked a peak move of +31.5% during that session. Argus tracked a trough of -17.3% from its starting point during tracking. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 24.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 26 | Clinical trial progress | Positive | +6.3% | First patient enrolled in final phase of PF614-MPAR-102 clinical study. |
| May 15 | Earnings update | Positive | +13.2% | Q1 2026 results with financing, trial progress, and strategic review update. |
| May 12 | Patent expansion | Positive | -17.1% | New Taiwan patent extending MPAR overdose-protection coverage through 2042. |
| May 08 | Conference presentation | Positive | -5.3% | CEO talk at Pain Therapeutics Summit Europe on TAAP and MPAR platforms. |
| Apr 16 | Clinical trial approval | Positive | -4.7% | IRB approval to start Part 3, final stage of PF614-MPAR-102 study. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ENSC news has produced mixed reactions, with some positive clinical and funding updates rallying the stock but several similarly positive items selling off.
Key Terms
breakthrough therapy regulatory
new drug application regulatory
nda regulatory
attention‑deficit/hyperactivity disorder medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection
SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced receipt of a Notice of Award for
This third year of funding completes Ensysce's
PF614-MPAR, which received Breakthrough Therapy designation from the U.S. FDA following their review of the initial clinical data from study PF614-101, represents a fundamentally new approach to opioid safety. Unlike conventional abuse-deterrent formulations, PF614-MPAR is designed to provide active protection against oral overdose-addressing a critical unresolved risk in opioid therapy. PF614-MPAR uses a proprietary chemical control mechanism that maintains therapeutic opioid exposure under prescribed use, while automatically limiting additional opioid release when excessive doses are ingested. This "built-in safety switch" introduces a new therapeutic paradigm: opioids engineered not only for efficacy, but for controlled exposure under conditions of misuse.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, noted that nearly 80,000 people in the U.S. die each year from opioid overdoses, with prescription opioids playing a significant role in the crisis2. "This continued NIDA funding allows us to keep advancing MPAR®, a new class of chemically engineered opioids designed to actively safeguard patients, even in situations involving misuse or dosing mistakes. This innovation marks an important step toward setting a new standard for opioid safety," she stated.
Beyond pain management, Ensysce's underlying TAAP™ and MPAR® platforms are designed to apply across multiple drug classes, an approach the Company is extending into additional therapeutic areas, including amphetamines and methadone, with the goal of providing safer treatment options for pain, attention‑deficit/hyperactivity disorder (ADHD), and opioid use disorder.
1 Research supporting this patent was funded by the National Institute on Drug Abuse of the National Institutes of Health under Award Number DA047682.
2 https://drugabusestatistics.org/opioid-epidemic/
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences, Inc.
View the original press release on ACCESS Newswire